ABBV Earnings Date & History
AbbVie Inc (NEW YORK STOCK EXCHANGE, INC.) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 6:23 PM ET
AbbVie Inc
Biotechnology
- Next earnings date
- Thursday, October 29, 2026
- Reporting session
- Time TBD
- EPS estimate
- $3.92
- Revenue estimate
- $17.65B
ABBV earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Friday, July 31, 2026 | Q2 2026 | $3.68 | $3.65 | -0.7% | $16.99B |
| Wednesday, April 29, 2026 | Q1 2026 | $2.65 | $2.65 | +0.2% | $15.00B |
| Wednesday, February 4, 2026 | Q4 2025 | $2.71 | $2.71 | +0.2% | $16.62B |
| Friday, October 31, 2025 | Q3 2025 | $1.81 | $1.86 | +2.7% | $15.78B |
| Thursday, July 31, 2025 | Q2 2025 | $2.94 | $2.97 | +0.9% | $15.42B |
What the market is watching in ABBV's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next ABBV earnings date?
- AbbVie Inc is scheduled to report on Thursday, October 29, 2026 (Time TBD). Dates can change until the company confirms them.
- Does ABBV report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for ABBV?
- Consensus EPS for the upcoming quarter is $3.92, on revenue of $17.65B.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
ABBV earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.